Syndax Pharmaceuticals, Inc. (SNDX) — 分析摘要
Syndax Pharmaceuticals, Inc.（SNDX）的市值为1.69十亿美元，最近一年的营收同比增长了+627.8%。净利润率为-165.6%。当前市盈率为-6.9倍。
核心要点
- 营收同比变化+627.8%
- 净利润率-165.6%
- 市盈率-6.9倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，SNDX的营收增长为+627.8%，市盈率为-6.9倍。
Syndax Pharmaceuticals, Inc. (SNDX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -55882.3x — 盈利不足以覆盖利息支出
D/E 为 8.3x — 杠杆极高
营业利润率为 -102.9% — 严重经营亏损
净利率为 -112.0% — 亏损超过收入（可能含一次性费用）
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
298
总部
NEW YORK, NY
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。